Brain Imaging of DSP-2342

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT07850102
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • SCHIZOPHRENIA 1 (Disorder)

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • DSP-2342 — DRUG
    a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia.

Study Details

The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.

Key Dates

First listed
Sep 30, 2026
Start date
Jan 1, 2027
Status verified
Sep 2026
Primary completion
Dec 31, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Evaluation of the neural effects of a single oral dose of DSP-2342
    The primary goal of this study is to evaluate the neural effects of a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia. The investigators will measure brain chemistry using magnetic resonance spectroscopy and brain activity using task-based functional MRI. The investigators will compare these measures before and after a single dose of DSP-2342.

Primary Outcome Measure

Glutamate levels (a.u.) [ Time Frame: one MRS scan on the same day of drug administration (acute effect) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
johns Hopkins UniversityBaltimoreMaryland21287
akira sawa, professor,, MD
443-846-1409

Find similar trials in Baltimore, MD

Related Studies